Please join us for a virtual seminar with Ono Pharmaceutical Co., Ltd. (ONO) and Ono Venture Investment, Inc. (OVI), its corporate venture capital arm to learn about innovation at the company, including ONO’s R&D, therapeutic and platform technology focus areas, science-led investment strategy and collaborative partnering approach – launching the call for Golden Ticket Competition entries to help accelerate innovative life science start-ups into real business that can bring value to patients.
Future Founders in Life Sciences: Nikole
Thursday, March 18, 2021 at 11:00 AM PST- Online Event
Continuing our new lecture series in partnership with Y Combinator, we’re excited to bring you Dr. Nikole Times of Siolta Therapeutics.
Her team is doing fascinating work developing novel microbiome-based therapeutics and diagnostics for the prevention and treatment of chronic inflammatory diseases, starting with atopic diseases.
About the Speaker:
Nikole E. Kimes, PhD is a co-founder and Chief Executive Officer of Siolta Therapeutics, a San Francisco biotech company developing novel microbiome-based therapeutics and diagnostics for the prevention and treatment of chronic inflammatory diseases, starting with atopic diseases.
Dr. Kimes heads a talented team of scientists, blending microbiology, immunology, and bioinformatics expertise to leverage microbiome data for the improvement of patient stratification and development of precision microbial therapeutics.
MBC BioLabs Partners with Curiox
MBC BioLabs is delighted to welcome Curiox as its newest partner. Curiox is placing a Laminar Wash™ MINI System at MBC BioLabs San Carlos 930 Brittan Fast-Track Core. The Laminar Wash MINI System employs the only suspension-cell sample preparation method that eliminates the centrifuge and the problems it introduces. It is an affordable bench-top instrument designed to produce the most quantitative and reproducible results for single cell sequencing and flow and mass cytometry.
Mitokinin Enters into Purchase Right Agreement with AbbVie
Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced that AbbVie, a leading global biopharmaceutical company and partner at MBC BioLabs, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound. Based on technology discovered at UCSF by Mitokinin co-founders Nicholas Hertz and Kevan Shokat, Mitokinin moved into MBC BioLabs San Francisco in September 2017 with Series A funding from a syndicate led by Mission BioCapital. Read full press release.